PAB
Melbourne, Australia; December 11, 2017: Patrys Limited (ASX: PAB), a therapeutic antibody development company, is pleased to announce that pre-clinical experiments with Patrys’ therapeutic candidate PAT-DX1 confirm that it acts synergistically with olaparib, the first approved PARP (poly (ADP-ribose) polymerase) inhibitor.
- Forums
- ASX - Day Trading
- Morning traders 11 / 12
Morning traders 11 / 12, page-64
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)